Radical innovation consists of research and development of new assets, whether they are synthetic, herbal medicines, biological, nutraceuticals, or dermocosmetics products. This research line requires a high investment cost and a long research period.
The company has been engaged in radical innovation research for more than 10 years, when it initially opted for phytomedicines and, today, continues to reinforce the importance of the subject by treating it as one of the cornerstones of its Strategic Planning.
All our actions converge on Aché’s goal to become the innovation leader among national pharmaceutical companies and to achieve a global reach.
Among the initiatives aimed at this objective, we highlight the Molecular Synthesis and Design Laboratory, launched in 2015 and focused mainly on radical innovation. It emphasizes the needs not yet met in different fields, such as gastroenterology sector, central nervous system, cardiometabolic area, respiratory health, osteomuscular system, and dermatology.
The release of this laboratory enabled Aché, in 2016, to enter the Structural Genomics Consortium (SGC), an international partnership between universities, governments, and pharmaceutical industries to speed up the development of new medicines.
In the company, innovation is essential and present not only in products and services, but in its broadest form, undergoing our processes, reaching the routine of each employee.